|
| |
CV TherapeuticsCV Therapeutics, Inc. (CVT), headquartered in Palo Alto, California, is a biopharmaceutical company focused on the discovery, development, and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. We apply advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery.
As a pioneer in the field of molecular cardiology, CV Therapeutics strives to discover new solutions for the unmet medical needs of patients. The company employs nearly 700 professionals, including a cardiovascular sales force of approximately 300 field-based individuals. Nearly 20 percent of employees based in our Palo Alto headquarters hold doctoral degrees, including MDs, PhDs, and PharmDs.
Key drivers of our business are to:
Identify, develop, and commercialize drugs primarily for cardiovascular disease,
Focus on small molecule drug candidates,
In-license cardiovascular products with unique potential, and
Commercialize products through concentrated sales and marketing efforts.
| Contact Details: |
| 3172 Porter Drive |
| Palo Alto |
| CA |
| 94304 |
| United States of America |
| Tel: | 650-384-8500 |
| Fax: | 650-858-0390 |
| Email: | webmaster@cvt.com |
| WWW: | www.cvt.com/
|
|
Loading...
|
Recent Publications by CV Therapeutics: |  |
Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.
We tested the effect of the antianginal agent ranolazine on ventricular... | 13th November, 2009
| CV Therapeutics, Inc., 3172 Porter Dr., Palo Alto, CA 94304, USA.
| Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1923-9. Epub 2009 Sep
DOI Direct Link |
A1 adenosine receptor: role in diabetes and obesity.
Adenosine mediates its diverse effects via four subtypes (A(1), A(2A),... | 25th September, 2009
| Department of Pharmacological Sciences, CV Therapeutics Inc., Palo Alto,
| Handb Exp Pharmacol. 2009;(193):271-95.
DOI Direct Link |
Recent developments in A2B adenosine receptor ligands.
A selective, high-affinity A(2B) adenosine receptor (AR) antagonist will... | 25th September, 2009
| Department of Medicinal Chemistry, CV Therapeutics Inc., Palo Alto, CA
| Handb Exp Pharmacol. 2009;(193):99-122.
DOI Direct Link |
The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction.
Palmitoyl-L-carnitine (PC), an ischemic metabolite, causes cellular Na(+)... | 20th August, 2009
| CV Therapeutics Inc, Palo Alto, California, USA.
| J Pharmacol Exp Ther. 2009 Aug;330(2):550-7. Epub 2009 Apr 29.
DOI Direct Link |
Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor.
BACKGROUND: Inherited human aldehyde dehydrogenase 2 (ALDH-2) deficiency... | 14th August, 2009
| CV Therapeutics, Palo Alto, CA, USA.
| Alcohol Clin Exp Res. 2009 Nov;33(11):1935-44. Epub 2009 Aug 10.
DOI Direct Link |
→View more CV Therapeutics research publications. |
Press Releases on CV Therapeutics:
|
 |
| NeurogesX Expands Commercial Operations Leadership Team |
5th November, 2009 |
NeurogesX |
-- Timothy Arendt has been named Vice President Sales. He will implement
and manage the U.S. specialty sales force for Qutenza(TM).
-- Amy C. Cavers has joined NeurogesX as
|
| NewCardio Expert to Present at Cardiac Safety Research Consortium Annual Meeting |
22nd October, 2009 |
NewCardio, Inc. |
SANTA CLARA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Sam George, NewCardio's
|
| CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors |
8th October, 2009 |
CardioDx |
PALO ALTO, Calif., Oct. 8 /PRNewswire/ -- CardioDx, a cardiovascular genomic diagnostics company, announced today the appointment of Louis G. Lange, M.D., Ph.D., as Chairman of the company's
|
| PTC Therapeutics Receives $2.6 Million in Government Grants |
15th June, 2009 |
PTC Therapeutics, Inc. |
- Funding supports continued focus on rare disorders -
SOUTH PLAINFIELD, N.J., June 15 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support
|
| PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration |
12th May, 2009 |
PTC Therapeutics, Inc. |
Project will advance novel platform for treatment of Spinal Muscular Atrophy
SOUTH PLAINFIELD, N.J. and NEW YORK, May 12 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and the Spinal Muscular Atrophy
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 16 individuals from CV Therapeutics using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 466 times since April 2007, the link to the organisation's website has been followed 65 times Recent Search Terms used to find this page: CVTX ABCA | layoffs at CV therapeutics | cv therapeutics company information news | . Search for more companies in Palo Alto Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for CV Therapeutics |
